Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a systemic vasculitis of small-to medium vessels, characterized by asthma, transient pulmonary infi...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on eosinophilic granulomatosis with polyangiitis is limited primarily due to its rarity, affecting fewer than 10 in 100,000 people. This low prevalence makes it challenging to conduct large-scale clinical studies. Additionally, the condition's clinical features can overlap with other diseases, complicating its characterization. As research continues, more information may become available, offering hope for better understanding and treatment options.
To manage eosinophilic granulomatosis with polyangiitis, it is essential to consult a rheumatologist or an immunologist with experience in vasculitis. You can also connect with the Churg Strauss Syndrome Association for support and resources at https://cssassociation.org. Participating in a patient registry or natural history study can provide valuable insights and contribute to research efforts. While genetic counseling is not currently indicated due to the lack of identified genetic factors, staying informed about ongoing research is crucial.
There are currently 20 active clinical trials investigating treatments for eosinophilic granulomatosis with polyangiitis. One FDA-approved treatment is benralizumab, while a small molecule selective Janus kinase (JAK) 1 inhibitor is designated for development. You can find more information on ongoing trials at ClinicalTrials.gov by searching for 'eosinophilic granulomatosis with polyangiitis'. This research landscape offers hope for improved therapies in the future.
Actionable guidance for navigating care for eosinophilic granulomatosis with polyangiitis
To manage eosinophilic granulomatosis with polyangiitis, it is essential to consult a rheumatologist or an immunologist with experience in vasculitis. You can also connect with the Churg Strauss Syndrome Association for support and resources at https://cssassociation.org. Participating in a patient registry or natural history study can provide valuable insights and contribute to research efforts. While genetic counseling is not currently indicated due to the lack of identified genetic factors, staying informed about ongoing research is crucial.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the eosinophilic granulomatosis with polyangiitis community
Helpful links for rare disease information and support
The documentation on eosinophilic granulomatosis with polyangiitis is limited primarily due to its rarity, affecting fewer than 10 in 100,000 people. This low prevalence makes it challenging to conduct large-scale clinical studies. Additionally, the condition's clinical features can overlap with other diseases, complicating its characterization. As research continues, more information may become available, offering hope for better understanding and treatment options.
To manage eosinophilic granulomatosis with polyangiitis, it is essential to consult a rheumatologist or an immunologist with experience in vasculitis. You can also connect with the Churg Strauss Syndrome Association for support and resources at https://cssassociation.org. Participating in a patient registry or natural history study can provide valuable insights and contribute to research efforts. While genetic counseling is not currently indicated due to the lack of identified genetic factors, staying informed about ongoing research is crucial.
There are currently 20 active clinical trials investigating treatments for eosinophilic granulomatosis with polyangiitis. One FDA-approved treatment is benralizumab, while a small molecule selective Janus kinase (JAK) 1 inhibitor is designated for development. You can find more information on ongoing trials at ClinicalTrials.gov by searching for 'eosinophilic granulomatosis with polyangiitis'. This research landscape offers hope for improved therapies in the future.
Actionable guidance for navigating care for eosinophilic granulomatosis with polyangiitis
To manage eosinophilic granulomatosis with polyangiitis, it is essential to consult a rheumatologist or an immunologist with experience in vasculitis. You can also connect with the Churg Strauss Syndrome Association for support and resources at https://cssassociation.org. Participating in a patient registry or natural history study can provide valuable insights and contribute to research efforts. While genetic counseling is not currently indicated due to the lack of identified genetic factors, staying informed about ongoing research is crucial.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the eosinophilic granulomatosis with polyangiitis community
Helpful links for rare disease information and support
The documentation on eosinophilic granulomatosis with polyangiitis is limited primarily due to its rarity, affecting fewer than 10 in 100,000 people. This low prevalence makes it challenging to conduct large-scale clinical studies. Additionally, the condition's clinical features can overlap with other diseases, complicating its characterization. As research continues, more information may become available, offering hope for better understanding and treatment options.
To manage eosinophilic granulomatosis with polyangiitis, it is essential to consult a rheumatologist or an immunologist with experience in vasculitis. You can also connect with the Churg Strauss Syndrome Association for support and resources at https://cssassociation.org. Participating in a patient registry or natural history study can provide valuable insights and contribute to research efforts. While genetic counseling is not currently indicated due to the lack of identified genetic factors, staying informed about ongoing research is crucial.
There are currently 20 active clinical trials investigating treatments for eosinophilic granulomatosis with polyangiitis. One FDA-approved treatment is benralizumab, while a small molecule selective Janus kinase (JAK) 1 inhibitor is designated for development. You can find more information on ongoing trials at ClinicalTrials.gov by searching for 'eosinophilic granulomatosis with polyangiitis'. This research landscape offers hope for improved therapies in the future.
Actionable guidance for navigating care for eosinophilic granulomatosis with polyangiitis
To manage eosinophilic granulomatosis with polyangiitis, it is essential to consult a rheumatologist or an immunologist with experience in vasculitis. You can also connect with the Churg Strauss Syndrome Association for support and resources at https://cssassociation.org. Participating in a patient registry or natural history study can provide valuable insights and contribute to research efforts. While genetic counseling is not currently indicated due to the lack of identified genetic factors, staying informed about ongoing research is crucial.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the eosinophilic granulomatosis with polyangiitis community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
2 peer-reviewed sources from PubMed
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning eosinophilic granulomatosis with polyangiitis
Updated Feb 20, 2026
Recent research highlights therapeutic advances in eosinophilic granulomatosis with polyangiitis, focusing on novel treatment strategies. These developments aim to improve patient outcomes and address unmet medical needs in this rare disease.
A large European cohort study identifies predictors of relapse and glucocorticoid dependence in eosinophilic granulomatosis with polyangiitis. These findings could inform treatment strategies and improve patient management.